Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent fight?
With its stock trading south of $200 after the big Restasis setback on the patent front, you can hear the growing buzz of analysts eagerly speculating about the chance that Allergan $AGN may soon be forced to break up the company to deliver for investors.
As you may have heard, a federal judge recently invalidated the Restasis patents for obviousness, the kind of slap down that has a high likelihood of standing up under appeal. So with its $1.5 billion franchise therapy teetering on the brink, it’s easy to see how hiving off Allergan’s stable and profitable aesthetics business — built around Botox — could work in its favor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.